SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

CockCardano ($COCK) is trending as the community rallies behind its real-world utility via Cocky Wings food truck, which fuels buybacks and offers a unique connection between crypto and physical goods; the community is also excited about their partnership with Snek energy drinks. The discussion highlights the token's strong community, RWA integration, and potential for passive income through staking in the arena.

Payoneer Global, Inc. is a financial technology company, which engages in providing a financial platform for small and medium-sized businesses to transact and do business. It operates through the Israel, United States, and All Other Countries geographical segments. The company was founded in 2005 and is headquartered in New York, NY.

Payoneer Global Inc

PAYO is trending amid mixed sentiment; while some investors are frustrated with the stock's performance and management's communication, others highlight its strong fundamentals and potential for a turnaround. The community is actively discussing valuation, potential catalysts, and the impact of broader market trends on PAYO. Analyst ratings and price target adjustments are also contributing to the conversation.

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending due to recent FDA approval of Revuforj for a specific type of leukemia, though discussions also involve a black box warning and how it compares to competitor Kura's drug. The community is weighing the clinical benefits against potential safety concerns and anticipating the impact on market share. Some are also speculating about a potential buyout before 2027.

Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.

Genprex Inc

GNPX is trending due to a mixed reaction to recent news and upcoming events, including a planned reverse stock split to regain NASDAQ compliance, which has sparked debate about management strategy. While some investors are optimistic about the potential for positive data from an upcoming conference on Reqorsa gene therapy to drive the stock price up, others express concern about potential dilution following the split. The community is actively discussing the implications of the reverse split and awaiting further developments from the conference.

Volatility Shares Trust - Volatility Shares Trust XRP ETF

XRP ETF

XRPI is trending due to speculation and excitement surrounding potential price appreciation following Ripple's partnerships and the possibility of an XRP ETF. Community members are actively discussing entry points and potential ROI, while some anticipate a rapid price surge. The broader context includes discussions around Ripple's role in global payments and the potential for XRP to gain further adoption.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CRMD is trending as the community discusses the potential impact of recent developments, including a new innovative technology designation for DefenCath and upcoming data readouts. Community members are actively debating revenue projections following the Melinta acquisition and potential catalysts that could drive the stock higher. Investors are also closely monitoring institutional ownership and short interest, while expressing concerns about share price suppression.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

PSKY is trending amid ongoing speculation about a potential acquisition of Warner Bros. Discovery, with community chatter focusing on deal valuations and potential partners. Discussions also involve optimism around cost-cutting measures and the UFC deal driving subscriber growth, although some express concern about the stock's low volume and ongoing market manipulation.

iRobot Corp. is a robot company, which engages in designing and building robots. The firm's products include robot vacuums and maps, and pool cleaners. It operates through Domestic and International geographical segments. The company was founded by Rodney Allen Brooks, Colin M. Angle, and Helen Greiner in August 1990 and is headquartered in Bedford, MA.

Irobot Corp

iRobot Corp

IRBT is trending as traders discuss potential short squeeze opportunities, noting its high short interest and small float. Some are drawing parallels to recent rallies in other heavily shorted stocks, while others speculate about a potential buyout given its history with Amazon and valuable IP. Community members are actively monitoring technical indicators and options activity, anticipating a possible price surge.

HCM II Acquisition Corp. operates as a blank check company. It was formed for the purpose of entering into a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 4, 2024 and is headquartered in Stamford, CT.

HCM II Acquisition Corp - Ordinary Shares - Class A

HCM II Acquisition Corp.

HCM II Acquisition Corp. ($HOND) is trending due to its upcoming merger with Terrestrial Energy and the ticker symbol change to $IMSR, generating significant buzz around its potential in the advanced nuclear technology sector. The community is comparing it to $OKLO, discussing its superior technology, larger market opportunity, and potential valuation catch-up, while also anticipating potential volatility typical of SPAC mergers. Some traders are speculating on a price drop post-merger, while others remain bullish, citing strong institutional ownership and the growing demand for nuclear energy to power AI data centers.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as it ventures into prediction markets through the acquisition of Railbird, aiming to expand beyond sports betting. While some view this as a strategic move to compete with platforms like Polymarket and tap into new revenue streams, others express concerns about potential regulatory hurdles and market saturation. Community discussions revolve around the deal's implications for DraftKings' long-term growth and its ability to navigate the evolving landscape of online gaming and predictions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

After a low period, biotech stocks are on the upswing, experts say

After a period of weakness, biotech stocks are on the upswing, experts say. But bear in mind: Putting your money into biotechnology companies can lead you on something of a wild ride.The field, which...

Emergent BioSolutions Inc. (EBS) on Friday said that it has secured new purchase orders from an international government partner for a multiproduct supply agreement.The agreement is valued at $29 million, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-secures-29-million-mcm-product-orders">said</a>. The order encompasses several product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism. The company said that this is the second procurement made by the same government this year.Shares of the company jumped 3% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:575/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_19_at_11_37_08_AM_png_46c276596d.webp" alt="EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits" width="575" height="61"><figcaption>EBS's Sentiment Meter and Message Volume as of 11:37 a.m. ET on Sept. 19, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock is “significantly undervalued,” while indicating that they see more than 100% upside.<stembedurl>https://stocktwits.com/NRG8/message/629302236</stembedurl>Another user expects the stock to hit $10 next week.<stembedurl>https://stocktwits.com/shoagh12/message/629291934</stembedurl>Emergent said it will receive about $26 million in 2025 under the agreement. This is in addition to more than $100 million in sales already generated for the company’s MCM portfolio outside the U.S. so far this year, it said.“Together with demand from the U.S. government, these international procurements reinforce the potential for our growth trajectory as part of Emergent’s multi-year transformation plan and highlights the strength of Emergent’s global footprint,” CEO Joe Papa said. The CEO also added that the company continues to see countries elevating their investment in defense preparedness.Emergent delivers solutions for health threats like Smallpox, Mpox, Botulism, Ebola, Anthrax, and Opioid overdose emergencies.Earlier this week, the company also announced that it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply Tembexa oral suspension. At the start of the month, the company also announced that a contract modification had been executed for $56 million to supply ACAM2000, a live vaccinia virus vaccine approved by the FDA for use in preventing Smallpox and Mpox in individuals at high risk of infection, to the U.S. government.EBS stock is down 14% this year but up approximately 17% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-likely-preparing-22to24-per-share-bid-for-warner-bros-discovery/chD34ulR3Ta">Paramount Skydance Likely Preparing $22 To $24 Per Share Bid For Warner Bros. Discovery: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Emergent BioSolutions Stock Rises After Receiving Fresh International Purchase Orders: Retail Says Stock Is ‘Significantly Undervalued’

The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.

Equity

The order encompasses multiple product offerings within Emergent’s medical countermeasures business, including countermeasures for threats posed by Smallpox, Anthrax, and Botulism.


Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment used for certain complications of the smallpox vaccine, to the U.S. government.The company’s shares closed 3.8% higher at $6.87 on Tuesday, with shares rising another 3.5% to $7.11 in after-hours trading.The new shipment is part of a long-term deal signed back in 2019 with the Administration for Strategic Preparedness and Response, a branch of the Department of Health and Human Services.&nbsp;CNJ-016 is used to treat uncommon but serious side effects from the smallpox vaccine, such as eczema vaccinatum and progressive vaccinia.&nbsp;It is not intended for&nbsp;the treatment of postvaccinal encephalitis or isolated vaccinia keratitis.&nbsp;The product comes with several safety considerations, including risks of allergic reactions, kidney issues, blood clots, and inaccurate blood sugar readings in some patients due to interference with glucose monitors.This latest modification comes shortly after a separate $62.4 million award on June 23, also from ASPR, for additional supply of Emergent’s botulism antitoxin, BAT.&nbsp;The BAT treatment is used in confirmed or suspected cases of botulism involving multiple neurotoxin types.In a separate update last week, the company expanded its NARCANDirect platform to include Kloxxado Nasal Spray 8 mg, an opioid overdose reversal medication.&nbsp;The online ordering system is available to groups, including first responders, schools, government agencies, and community-based programs focused on naloxone distribution.On Stocktwits, retail sentiment was ‘neutral’ amid ‘normal’ message volume.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions’ stock</a> has risen 33.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy

The company also secured a $62.4 million modification to its botulism antitoxin supply contract and recently expanded its NARCANDirect platform to include a new opioid overdose reversal spray.

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions

Emergent Biosolutions (EBS) Q1 Earnings Top Estimates

Shares of Emergent BioSolutions plunged more than 8% in after-hours trading on Monday after the company reported a steep revenue drop in the fourth quarter.&nbsp;While Emergent swung to a profit, the earnings beat failed to offset concerns over its shrinking top line.The medical contract development and manufacturing firm posted adjusted net income of $0.05 per diluted share, a sharp reversal from the $0.77 per share loss a year earlier. Analysts had expected a loss of $0.43 per share.&nbsp;However, quarterly revenue fell to $194.7 million from $276.6 million a year ago, well below the consensus estimate of $249.5 million.For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.&nbsp;For 2025, the company projected revenue of $750 million to $850 million, significantly trailing the $1.11 billion analysts had expected.“We delivered favorable full-year financial results driven by our core products, all the while completing a series of strategic stabilization actions to strengthen our financial position ahead of plan,” CEO Joe Papa said.&nbsp;“This strong foundation enables Emergent to focus on profitable revenue growth and cash generation as we move forward with turnaround activities, a critical phase in our multi-year transformation plan.”Despite the revenue shortfall, retail traders on Stocktwits remained optimistic, with sentiment for EBS ending Monday in the ‘bullish’ zone.&nbsp;Many users focused on the company’s improving profitability rather than its shrinking revenue.&nbsp;One trader compared the current situation to a period before Emergent had its Narcan opioid overdose nasal spray in its portfolio, arguing that profitability was the key factor.<stembedurl>https://stocktwits.com/WinstonSmith33/message/606629996</stembedurl>Another user pointed to CEO Joe Papa’s comments on the earnings call, noting that the company’s 2025 guidance appeared “conservative.”&nbsp;<stembedurl>https://stocktwits.com/GrantDiaz/message/606587312</stembedurl>Some traders speculated that Emergent’s mpox vaccine sales had not yet been factored into the guidance.&nbsp;While the company’s smallpox vaccine has been used for mpox, it has not yet&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">received</a> formal FDA approval for that indication.<a href="https://stocktwits.com/symbol/EBS">Emergent BioSolutions shares</a> are down more than 28% year-to-date but have more than doubled over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 30%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.

Emergent BioSolutions Stock Sinks As Q4 Revenue Plunges 40%, But Retail Clings To Profit Swing

For the first quarter, Emergent forecasted revenue in the range of $200 million to $240 million, lower than an analyst estimate of $279 million.


Shares of GeoVax Labs Inc. (<a class="mention" data-mention="$GOVX" data-symbol-id="GOVX" href="https://stocktwits.com/symbol/GOVX" target="_blank">$GOVX</a>), SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), and Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>) gained in mid-day trading on Friday after the World Health Organisation (WHO) reaffirmed that the ongoing upsurge of mpox remains a public health emergency of international concern (PHEIC).Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus.&nbsp;“The decision was based on the rising number and continuing geographic spread of cases, operational challenges in the field, and the need to mount and sustain a cohesive response across countries and partners,” the apex health agency said in a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WHO/status/1860015125463175343">post</a> on X (formerly Twitter).&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_132250_27d9a22ffc.png" alt="Screenshot 2024-11-22 132250.png">The WHO first declared mpox a PHEIC in August earlier this year because a new strain of the virus, Clade Ib, had spread to countries that had not previously reported any incidences of the disease, like Thailand and Sweden.&nbsp;Shares of GeoVax, currently working on a vaccine for mpox and smallpox, were up nearly 10% in mid-day trading on Friday. The stock has lost 47% of its value this year so far.&nbsp;<stembedurl>https://stocktwits.com/gabbs/message/593724551</stembedurl>Meanwhile, shares of SIGA Technologies Inc. (<a class="mention" data-mention="$SIGA" data-symbol-id="SIGA" href="https://stocktwits.com/symbol/SIGA" target="_blank">$SIGA</a>), developing an investigational drug for treating mpox called tecovirimat (TPOXX),&nbsp; jumped 2.5% after the news.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134247_8c8f14c041.png" alt="Screenshot 2024-11-22 134247.png">Retail sentiment around the stock improved to ‘bullish’ (60/100) from ‘neutral’ a day ago.&nbsp;SIGA Technologies’ shares have gained 11% this year so far.There was less movement around Emergent Biosolutions Inc. (<a class="mention" data-mention="$EBS" data-symbol-id="EBS" href="https://stocktwits.com/symbol/EBS" target="_blank">$EBS</a>), also working on a vaccine for mpox, which saw a marginal uptick of 0.6% in mid-day trading on Friday.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_22_134547_d67811671e.png" alt="Screenshot 2024-11-22 134547.png">Retail sentiment around the stock remained in the ‘neutral’ zone with no significant change in chatter.&nbsp;Emergent Biosolutions’ vaccine, approved for smallpox, has also been used as a mpox shot, but the U.S. Food and Drug Administration is yet to approve its application for use against the virus.<stembedurl>https://stocktwits.com/WinstonSmith33/message/593679534</stembedurl>In 2022, the company acquired the rights to a smallpox treatment called Tembexa, which was developed by Chimerix Inc. ($CMRX), for up to $337.5 million plus royalties.Chimerix was up around 0.6% as well during mid-day trading.&nbsp;For updates and corrections email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/agrify-stock-doubles-to-hit-over-1-year-high-after-25-9-m-placement-but-retail-wary-of-short-covering-rally/cJIdTKHRg3">Agrify Stock Doubles To Hit Over 1-Year High After $25.9M Placement, But Retail Wary Of Short-Covering Rally</a>

Mpox, formerly called monkeypox, is a disease similar to smallpox caused by a virus. | Source: Pexels

GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks

Emergent Biosolutions and Chimerix also saw marginal gains after the announcement. 

The S&amp;P 500 Index, a broader gauge of stock market performance, finished the week ended Nov. 8 at a record high amid the euphoria over a decisive win for the Republican Party candidate Donald Trump in the 2024 presidential election.The 30-stock Dow Jones Industrial Average and the tech-heavy Nasdaq Composite also ended in uncharted territory.&nbsp;As the new week unfolds, earnings and economic data will once again dictate sentiment. About 91% of the S&amp;P 500 companies have reported already, and the cumulative earnings growth of S&amp;P 500 companies is now estimated at 5.3%,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://advantage.factset.com/hubfs/Website/Resources%20Section/Research%20Desk/Earnings%20Insight/EarningsInsight_110824.pdf">according</a> to Factset.The first-tier economic data/events for the week include the October consumer and producer price inflation reports, due on Wednesday and Thursday, respectively,&nbsp; the October retail sales report due on Friday and speeches by a slew of Federal Reserve officials.As the new week kickstarts, the following stocks are eliciting the most bullish/bearish reactions from retailers on the Stocktwits platformMost BullishMarathon Digital Holdings, Inc. ($MARA)Bitcoin miner Marathon Digital generated the most bullish sentiment, apparently due to the strength seen in the cryptocurrency space, especially the Bitcoin ($BTC.X). The a<a href="https://stocktwits.com/news-articles/markets/equity/bitcoin-hits-record-high-on-sunday/cJ4gJ3oRax">pex crypto crossed the $80,000 threshold</a> on Sunday and the momentum continued unabated on Monday. Bitcoin rallied past the $81,000 mark early Monday.BlackRock, Inc. ($BLK)Asset manager BlackRock was in the news last Thursday as media reports&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/c811be5f-73aa-4565-8901-f0eacdbad0bc">said</a> the company is in discussions to buy a small equity stake in hedge fund Millennium Management. Millennium is one of the most profitable hedge fund and if the rumors prove to be true, it would mark the first time in the firm’s 35-year history that it is taking an outside investment, Financial Times reportedCoinbase Global, Inc. ($COIN)Cryptocurrency exchange Coinbase may also be riding the crypto strength. In late-October, the company reported an increase in its third-quarter revenue from $623 million in 2023 to $1.13 billion in 2024. But both the earnings per share and revenue trailed expectations due to a muted crypto trading environment.Emergent Biosolutions, Inc. ($EBS)&nbsp;Shares of Emergent Biosolutions, a contract development and manufacturing organization, have picked up some momentum following the company’s quarterly results announced late Wednesday. The stock has tacked on over 31% since then.Netflix, Inc. ($NFLX)Streaming giant Netflix hasn't had any company-specific news or analysts’ action to impact the stock. However, AMC Entertainment Holdings, Inc. ($AMC) said last week its third quarter benefited from a new deal with Netflix for prior seasons of AMC series called the AMC Collection.Most BearishBaidu, Inc. (BIDU)Chinese search giant Baidu drew negative sentiment from retailers. Friday, the stock shed nearly 5% amid muted reaction to additional China stimulus and fears concerning a Trump backlash on overseas companies. Media reports said Baidu will launch its new AI-powered smart glasses at the Baidu World Event in Shanghai on Tuesday. The negative sentiment may also be partly due to investor apprehensions over whether the company can give Meta Platforms, Inc.’s ($META) Ray Ban smart glasses a run for the money.Aurinia Pharmaceuticals, Inc. ($AUPH)Kidney drug company Aurinia failed to attract a buyer after activist hedge fund MKT Capital forced the&nbsp; company to explore strategic initiatives, including a sale. While reporting its financial results last week, the Canadian biotech announced its decision to cut 45% of its workforce in a bid to save cost.Pinduoduo, Inc. ($PDD)General skepticism toward China stocks and domestic competition may have dented sentiment toward Chinese online retailer Pinduoduo.Evolent Health, Inc. ($EVH)Shares of Evolent are languishing at multi-year lows following Friday’s 45%+ plunge in reaction to its lackluster quarterly results. The specialty care management services company that focuses on&nbsp;oncology, cardiology, and musculoskeletal markets in the U.S. was scouting for a buyer earlier this year.Checkpoint Therapeutics, Inc. ($CKPT)Waltham, Massachusetts-based Checkpoint Therapeutics, a clinical-stage,&nbsp;immunotherapy and targeted-oncology company, hasn’t had any stock-moving catalysts.&nbsp;Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/fifth-third-executive-weighs-in-on-election-impact/cJ4ginFRaC">Fifth Third CFO Bryan Preston Sees Trump’s 2024 Presidential Election Win Double-Edged Sword</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

Crypto rally has improved sentiment toward stocks with exposure to them.

10 Stocks Retailers On Stocktwits Are Most Bullish/Bearish About To Start The Week

As the new week unfolds, earnings and economic data will again dictate sentiment. 

Shares of Emergent Biosolutions ($EBS) soared 23% (3 pm ET) Thursday after the company reported strong third-quarter results, lifting retail sentiment.Earnings per share for Q3 came in at $1.37, compared to consensus estimates of $0.10, a whopping 1225.81% difference. Revenues stood at $293.8 million, up from $270.5 million last year, driven by operational improvements. Wall Street had estimated revenues at $290.33 million. In addition, it has raised its FY24 revenue outlook to $1.05B-$1.13B."Through disciplined execution and steady, measurable progress, Emergent's financial position is the strongest it has been since 2021 as evidenced by our favorable third-quarter results," Emergent chief executive, Joe Papa, said in a statement, "We have successfully improved efficiencies and refocused our operations related to customer demand, generated value in our core medical countermeasures and NARCAN Nasal Spray businesses and refinanced our debt leading to increased revenue and cash flow.”Retail sentiment for the stock turned ‘extremely bullish’ from ‘neutral’ a day ago. Meanwhile, message volumes were at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1300/290;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_08_at_1_28_37_AM_1cc65c7185.png" alt="Screenshot 2024-11-08 at 1.28.37 AM.png" width="1300" height="290"><figcaption>EBS Sentiment meter and message volumes on Nov 7 as of 3:05 pm ET</figcaption></figure>Emergent is hoping to capitalize on the ongoing public health crises like the opioid overdose epidemic and the Mpox outbreak. On Thursday, it also named &nbsp;Simon Lowry, M.D., as chief medical officer and head of research and development. Lowry, who was previously CEO at Mysthera Therapeutics, will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical and biostatistics, and patient safety.One Stocktwits user suggested the stock could more than double in value over time, with the recent developments.<stembedurl>https://stocktwits.com/manutd123/message/591609601</stembedurl>Emergent’s stock is up 343.6% year-to-date.For updates and corrections, email newsroom@stocktwits.com &nbsp;

Retail sentiment for the stock turned ‘extremely bullish’| Source: Pixabay

Emergent Biosolutions Stock Soars After Q3 Earnings: Retail Sentiment Strong

Earnings per share for Q3 came in at $1.37, compared to consensus estimates of $0.10.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$9.74
Prev Close	$9.66
Open	$9.85
Dividend Yield	0.00%
50-Day Moving Average	$8.79
Beta	2.32
Avg. Volume	1M
PE Ratio	3.97

52-Week High	$12.73
52-Week Low	$4.02
Market Capitalization	$519.64M
EPS (Annual)	-$3.60
Price to Book	0.98
Revenue Per Employee	$1.16M
Enterprise Value/EBITDA	N/A

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EBS News

EBSEmergent Biosolutions Inc